Last reviewed · How we verify
Mepolizumab 250
Mepolizumab 250 is a Anti-IL-5 monoclonal antibody Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development for Asthma, Eosinophilic granulomatosis with polyangiitis (EGPA).
Interleukin-5 antagonist
Interleukin-5 antagonist Used for Asthma, Eosinophilic granulomatosis with polyangiitis (EGPA).
At a glance
| Generic name | Mepolizumab 250 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Anti-IL-5 monoclonal antibody |
| Target | IL-5 |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Mepolizumab is a recombinant humanized IgG1 monoclonal antibody that selectively binds to and neutralizes interleukin-5 (IL-5), a cytokine involved in the pathogenesis of asthma and eosinophilic granulomatosis with polyangiitis (EGPA).
Approved indications
- Asthma
- Eosinophilic granulomatosis with polyangiitis (EGPA)
Common side effects
- Injection site reaction
- Headache
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma (PHASE2)
- Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mepolizumab 250 CI brief — competitive landscape report
- Mepolizumab 250 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Mepolizumab 250
What is Mepolizumab 250?
How does Mepolizumab 250 work?
What is Mepolizumab 250 used for?
Who makes Mepolizumab 250?
What drug class is Mepolizumab 250 in?
What development phase is Mepolizumab 250 in?
What are the side effects of Mepolizumab 250?
What does Mepolizumab 250 target?
Related
- Drug class: All Anti-IL-5 monoclonal antibody drugs
- Target: All drugs targeting IL-5
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Asthma
- Indication: Drugs for Eosinophilic granulomatosis with polyangiitis (EGPA)
- Compare: Mepolizumab 250 vs similar drugs
- Pricing: Mepolizumab 250 cost, discount & access